Croteau Dominique, Qin Fuzhong, Chambers Jordan M, Kallick Ethan, Luptak Ivan, Panagia Marcello, Pimentel David R, Siwik Deborah A, Colucci Wilson S
Cardiovascular Medicine Section and Myocardial Biology Unit, Boston University School of Medicine, Boston, Massachusetts.
JACC Basic Transl Sci. 2020 Sep 9;5(9):916-927. doi: 10.1016/j.jacbts.2020.07.006. eCollection 2020 Sep.
Mice with obesity and metabolic heart disease (MHD) due to a high-fat, high-sucrose diet were treated with placebo, a clinically relevant dose of sacubitril (SAC)/valsartan (VAL), or an equivalent dose of VAL for 4 months. There were striking differences between SAC/VAL and VAL with regard to: 1) diastolic dysfunction; 2) interstitial fibrosis; and to a lesser degree; 3) oxidative stress-all of which were more favorably affected by SAC/VAL. SAC/VAL and VAL similarly attenuated myocardial hypertrophy and improved myocardial energetics. In mice with obesity-related MHD, neprilysin inhibition exerts favorable effects on diastolic function.
因高脂高糖饮食而患有肥胖症和代谢性心脏病（MHD）的小鼠，分别接受安慰剂、临床相关剂量的沙库巴曲（SAC）/缬沙坦（VAL）或等量VAL治疗4个月。SAC/VAL与VAL在以下方面存在显著差异：1）舒张功能障碍；2）间质纤维化；以及在较小程度上的3）氧化应激——所有这些方面SAC/VAL的影响更为有利。SAC/VAL和VAL同样减轻了心肌肥大并改善了心肌能量代谢。在患有肥胖相关MHD的小鼠中，抑制中性肽链内切酶对舒张功能产生有利影响。
